Matches in Wikidata for { <http://www.wikidata.org/entity/Q90392271> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q90392271 description "article scientifique publié en 2018" @default.
- Q90392271 description "artículu científicu espublizáu en xunetu de 2018" @default.
- Q90392271 description "scientific article published on 03 July 2018" @default.
- Q90392271 description "wetenschappelijk artikel" @default.
- Q90392271 description "наукова стаття, опублікована в липні 2018" @default.
- Q90392271 name "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 name "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 type Item @default.
- Q90392271 label "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 label "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 prefLabel "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 prefLabel "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 P1433 Q90392271-419433DD-D812-40DA-87FA-659021B9DC8D @default.
- Q90392271 P1476 Q90392271-F3896CE3-6880-44DF-8C04-4FC064DD8D92 @default.
- Q90392271 P2093 Q90392271-02B3412E-35A6-4CF2-BA1D-8C1372A8907C @default.
- Q90392271 P2093 Q90392271-217C5853-A88E-4E5F-A4E7-00AF8CA40D04 @default.
- Q90392271 P2093 Q90392271-2E6D76F8-8BDE-4070-BEBA-78C5C9F356DB @default.
- Q90392271 P2093 Q90392271-5883AC3D-7FBB-4D5C-95C7-7FB4C577C192 @default.
- Q90392271 P2093 Q90392271-5A4B2BB0-28E7-4ECE-80E3-9196F4B19CA0 @default.
- Q90392271 P2093 Q90392271-5FA2E229-02D2-4292-AA04-96389777CE9E @default.
- Q90392271 P2093 Q90392271-8F5171F4-CFF2-4438-9C7E-5EBA04A717F1 @default.
- Q90392271 P2093 Q90392271-9840D910-38BD-4E88-ABCC-C936FDE095B5 @default.
- Q90392271 P2093 Q90392271-A200BCAC-5D4B-40A5-A7ED-50C56A18DF58 @default.
- Q90392271 P2093 Q90392271-A71B77E6-9B73-4060-8EA2-1E137A82C944 @default.
- Q90392271 P2093 Q90392271-B474631F-66B5-4EB7-A876-4CA10F9ECA48 @default.
- Q90392271 P2093 Q90392271-BCD1FA7A-DBFE-4542-9CC4-B42C55A1DF4B @default.
- Q90392271 P2093 Q90392271-CB7D4A5A-7583-4CAD-BC3B-0E1BD085974C @default.
- Q90392271 P2093 Q90392271-EB7247B2-72BB-4E7D-8281-4BF510549445 @default.
- Q90392271 P304 Q90392271-8F29AF67-4DCC-4324-9FBA-4B528A9A13D0 @default.
- Q90392271 P31 Q90392271-F41F9264-1321-4E72-B2F2-CB0FE49F5B13 @default.
- Q90392271 P356 Q90392271-BD2E5736-D4D7-4642-9AE6-BB8FEB0A3ADE @default.
- Q90392271 P433 Q90392271-43A9A318-F2F2-4B08-96BF-066CCB68F4A0 @default.
- Q90392271 P478 Q90392271-2AFA7CBB-3CEB-4F71-B97C-23CCBAA2A81C @default.
- Q90392271 P50 Q90392271-1045AC66-EE3C-4193-87E2-7CAFC4A8277E @default.
- Q90392271 P50 Q90392271-10DB122F-3645-45ED-B1FD-60A433F7F3AA @default.
- Q90392271 P50 Q90392271-332EC0F3-A33F-47ED-9A9E-CFAF3A269AE3 @default.
- Q90392271 P50 Q90392271-9D14B6C3-50D3-485D-942F-7DCDC1742053 @default.
- Q90392271 P50 Q90392271-AA78E637-2409-4105-8F94-C21A70757407 @default.
- Q90392271 P577 Q90392271-7D0BFBE9-0688-4318-B4B5-C365407FA79F @default.
- Q90392271 P698 Q90392271-6F5351A5-0FC8-4C19-9018-CD4AE2FB8236 @default.
- Q90392271 P921 Q90392271-386A4E41-716B-4CAB-8FFC-DAFBB26D40E7 @default.
- Q90392271 P921 Q90392271-AAAAEEDD-2439-45A4-9746-8A783E433FCE @default.
- Q90392271 P921 Q90392271-ECD3C42D-6266-488F-A9A8-AB92B3001881 @default.
- Q90392271 P356 J.CLLC.2018.06.005 @default.
- Q90392271 P698 30033090 @default.
- Q90392271 P1433 Q332299 @default.
- Q90392271 P1476 "RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma" @default.
- Q90392271 P2093 "Alessandra Fabbri" @default.
- Q90392271 P2093 "Annalisa Trama" @default.
- Q90392271 P2093 "Eliana Rulli" @default.
- Q90392271 P2093 "Giancarlo Pruneri" @default.
- Q90392271 P2093 "Giovannella Palmieri" @default.
- Q90392271 P2093 "Lital Hollander" @default.
- Q90392271 P2093 "Marina Chiara Garassino" @default.
- Q90392271 P2093 "Martina Imbimbo" @default.
- Q90392271 P2093 "Massimo Broggini" @default.
- Q90392271 P2093 "Milena Vitali" @default.
- Q90392271 P2093 "Monica Ganzinelli" @default.
- Q90392271 P2093 "Paolo Zucali" @default.
- Q90392271 P2093 "Rossana Berardi" @default.
- Q90392271 P2093 "Valter Torri" @default.
- Q90392271 P304 "e811-e814" @default.
- Q90392271 P31 Q13442814 @default.
- Q90392271 P356 "10.1016/J.CLLC.2018.06.005" @default.
- Q90392271 P433 "5" @default.
- Q90392271 P478 "19" @default.
- Q90392271 P50 Q37829911 @default.
- Q90392271 P50 Q39677318 @default.
- Q90392271 P50 Q57054219 @default.
- Q90392271 P50 Q57624011 @default.
- Q90392271 P50 Q58445152 @default.
- Q90392271 P577 "2018-07-03T00:00:00Z" @default.
- Q90392271 P698 "30033090" @default.
- Q90392271 P921 Q415588 @default.
- Q90392271 P921 Q423762 @default.
- Q90392271 P921 Q42824440 @default.